newsfilter
← Latest News
Business Wire·

Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic